BioSpace News Archive

International experts treating COVID-19 patients have concluded that hemodynamic optimization plays a major role in the management of the complex interaction of respiratory and cardiovascular factors.

The new locations for Tampa General Hospital Cancer Care will be TGH’s first locations on the east coast of Florida.

Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its next generation Sonata® System 2.1 for Transcervical Fibroid Ablation (TFA). The Sonata techno

I-MED Pharma Inc., a Canadian medical device company, announced today that it is collaborating with KMG International Limited to manufacture and supply personal protective equipment (PPE) and COVID-19 diagnostic tests to help respond to the urgent need for these products in Canada, the United States, and Europe.

POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management team will participate in several upcoming virtual investor conferences held in June 2020. Jefferies Virtual Healthcare Conference 2020 Date: June 2-

New research published today in the Journal of NeuroInterventional Surgery (JNIS) shows ischemic stroke patients are arriving to hospitals and treatment centers an average of 160 minutes later during the COVID-19 pandemic, as compared with a similar timeframe in 2019

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Quest Diagnostics Self-collection Kit for COVID-19 (self-collection kit)

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates targeting cancers in areas of high unmet medical need, announced that it intends to offer and sell shares of its common stock in an underwritten public offering of 5 million shares of its common stock.

Protalix BioTherapeutics, Inc. together with Chiesi Global Rare Diseases announced the submission on May 27, 2020 of a Biologics License Application to the U.S. Food and Drug Administration for pegunigalsidase alfa for the proposed treatment of adult patients with Fabry disease via the FDA’s Accelerated Approval pathway.

Demonstrating Sustained Improvements and Even Greater Stabilization in Patients Starting Earlier Treatment.